Adjuvant immunotherapy for locally advanced renal cell carcinoma

Introduction Locally advanced renal cell carcinoma (RCC) presents a therapeutic challenge due to 20–40% relapse risk post-nephrectomy. There has been substantial interest in utilizing immunotherapy interrupting the PD-1/PD-L1 axis in the perioperative space, especially in the adjuvant setting, in order to minimize such risk.